Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 20

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 20
---
 available;

•

the costs, timing, and results, of Liminatus’s preclinical studies and clinical trials, as well as the number of required trials for regulatory approval and the criteria for success in such trials;

•

potential delays and uncertainties in Liminatus’s anticipated timelines and milestones and additional costs associated with the impact of the residual effects of the coronavirus pandemic on our clinical trial operations;

•

legal and regulatory developments in the United States, or U.S., and foreign countries, including any actions or advice that may affect the design, initiation, timing, continuation, progress or outcome of clinical trials or result in the need for additional clinical trials;

•

cost of complying with current laws and regulations and any changes in applicable laws or regulations;

•

the ability to protect and enhance Liminatus’s corporate reputation and brand;

•

the impact from future regulatory, judicial, and legislative changes in Liminatus’s industry;

•

Liminatus’s ability to obtain and maintain regulatory approval of any of its product candidates;

•

Liminatus’s ability to research, discover and develop additional product candidates;

•

risks related to manufacturing active pharmaceutical ingredients, drug product, and other materials we need;

•

the performance of third parties upon which Liminatus depends, including contract research organizations, contract manufacturing organizations, contract laboratories, and independent contractors;

•

Liminatus’s ability to grow and manage growth profitably;

•

Liminatus’s ability to obtain and maintain intellectual property protection and not infringe on the rights of others;

•

Liminatus’s ability to limit its exposure under product liability lawsuits;

•

the inability to develop and maintain effective internal controls;

•

the impact of the COVID-19 pandemic and other similar disruptions in the future;

•

those factors set forth in documents of Iris filed, or to be filed, with SEC;

•

other factors that the Iris and Liminatus may not have currently identified or quantified; and

•

other factors detailed under the section entitled “ Risk Factors .”

**The forward-looking statements contained in this proxy statement/prospectus are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described herein under “Risk Factors”. Should one or more